These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 32206854

  • 1. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 4. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 5. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A.
    Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY, Dong YJ, Yin Y, Xu WL, Liang ZY, Wang Q, Li Y, Liu W, Ou JP, Ren HY.
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov 14; 42(11):904-910. PubMed ID: 35045651
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A, Hallböök H, Arvidson J, Sällström K, Bondeson K, Pauksens K.
    Leuk Lymphoma; 2018 May 14; 59(5):1172-1179. PubMed ID: 28831836
    [Abstract] [Full Text] [Related]

  • 10. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 14; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 11. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M, Wackenheim C, Germi R, Carré M, Bulabois CE, Thiébaut A, Lupo J, Semenova T, Cahn JY, Morand P, Epaulard O.
    Transpl Infect Dis; 2016 Dec 14; 18(6):889-895. PubMed ID: 27696681
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.
    Marjańska A, Pogorzała M, Dziedzic M, Czyżewski K, Richert-Przygońska M, Dębski R, Bogiel T, Styczyński J.
    Front Immunol; 2024 Dec 14; 15():1427637. PubMed ID: 39055711
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Dec 14; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 16. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
    Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F.
    Am J Transplant; 2007 Jun 14; 7(6):1648-55. PubMed ID: 17511690
    [Abstract] [Full Text] [Related]

  • 17. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB, Wang Y, Song QJ, Shen DH.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep 14; 41(9):607-12. PubMed ID: 23157829
    [Abstract] [Full Text] [Related]

  • 18. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X, Zhu Q, Qiu H, Chen F, Xue S, Ma X, Sun A, Wu D.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb 14; 37(2):138-43. PubMed ID: 27014984
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.